Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
McGill University Health Centre/Research Institute of the McGill University Health Centre
ImmunityBio, Inc.
Seagen Inc.
Ascendis Pharma A/S
Royal Marsden NHS Foundation Trust
University of Iowa
Vividion Therapeutics, Inc.
University of Erlangen-Nürnberg Medical School
Sotio Biotech Inc.
M.D. Anderson Cancer Center
Astellas Pharma Inc
Wake Forest University Health Sciences
M.D. Anderson Cancer Center